0000899243-19-001178.txt : 20190115
0000899243-19-001178.hdr.sgml : 20190115
20190115100116
ACCESSION NUMBER: 0000899243-19-001178
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181116
FILED AS OF DATE: 20190115
DATE AS OF CHANGE: 20190115
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vexler Vladimir
CENTRAL INDEX KEY: 0001759506
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36721
FILM NUMBER: 19526366
MAIL ADDRESS:
STREET 1: 333 TWIN DOLPHIN DRIVE
STREET 2: SUITE 600
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Coherus BioSciences, Inc.
CENTRAL INDEX KEY: 0001512762
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 273615821
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: C/O DENNIS M. LANFEAR
STREET 2: 333 TWIN DOLPHIN DR, SUITE 600
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: (650) 649-3530
MAIL ADDRESS:
STREET 1: C/O DENNIS M. LANFEAR
STREET 2: 333 TWIN DOLPHIN DR, SUITE 600
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: BioGenerics, Inc.
DATE OF NAME CHANGE: 20110210
3/A
1
doc3a.xml
FORM 3/A SUBMISSION
X0206
3/A
2018-11-16
2018-11-20
0
0001512762
Coherus BioSciences, Inc.
CHRS
0001759506
Vexler Vladimir
COHERUS BIOSCIENCES, INC.
333 TWIN DOLPHIN DRIVE, SUITE 600
REDWOOD CITY
CA
94065
0
1
0
0
Chief Scientific Officer
Common Stock, $0.0001 par value
7828
D
Stock Option (right to buy)
2.0838
2023-02-28
Common Stock
71982
D
Stock Option (right to buy)
29.00
2025-04-01
Common Stock
25000
D
Stock Option (right to buy)
14.43
2026-02-26
Common Stock
25000
D
Stock Option (right to buy)
17.17
2026-05-11
Common Stock
24618
D
Stock Option (right to buy)
20.15
2027-04-03
Common Stock
25000
D
Stock Option (right to buy)
12.70
2027-08-06
Common Stock
50000
D
Stock Option (right to buy)
9.30
2027-11-15
Common Stock
25000
D
Stock Option (right to buy)
10.05
2028-02-01
Common Stock
75000
D
This Form 3 amendment has been filed solely to correct the amount of securities beneficially owned as shown in Table I, column 2 of both the original Form 3 and the Form 3A.
The original grant was for 86,982 shares, of which 15,000 shares have been exercised and sold. The remaining shares underlying this option are fully vested and exercisable as of the date hereof.
A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from April 1, 2015, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from March 1, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from May 6, 2016, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from April 3, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
A portion of the shares underlying this option are vested and exercisable as of the date hereof. The underlying shares subject to the option vest and become exercisable over two years as follows: Fifty percent (50%) of the underlying shares subject to the option vest and become exercisable on August 1, 2018, an additional twenty-five percent (25%) of the underlying shares subject to the option vest and become exercisable on February 1, 2019 and twenty-five percent (25%) of the underlying shares subject to the option vest and become exercisable on August 1, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from November 15, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
A portion of the shares underlying this option are vested and exercisable as of the date hereof. The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
/s/ Jean Frederic Viret, as Attorney-in-Fact for Vladimir Vexler
2019-01-15